Continue Reading Below
Dublin, Ireland - January 19, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG)
(the "Company") announces that Thomas Dittrich will assume his role as
Chief Financial Officer, and become an Executive member of the Board of
Directors and a member of the Executive Committee, on March 19, 2018.
This announcement is made in compliance with LR 9.6.12.
For further information please contact:
Christoph Brackmann email@example.com +41 795 432 359
Sun Kim firstname.lastname@example.org +1 617 588 8175
Robert Coates email@example.com +44 203 549 0874
Lisa Adler firstname.lastname@example.org +1 617 588 8607
Katie Joyce email@example.com +1 781 482 2779
NOTES TO EDITORS
Shire is the global leader in serving patients with rare diseases. We
strive to develop best-in-class therapies across a core of rare disease
areas including hematology, immunology, genetic diseases, neuroscience,
and internal medicine with growing therapeutic areas in ophthalmics and
oncology. Our diversified capabilities enable us to reach patients in
more than 100 countries who are struggling to live their lives to the
We feel a strong sense of urgency to address unmet medical needs and
work tirelessly to improve people's lives with medicines that have a
meaningful impact on patients and all who support them on their journey.
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
Source: Shire plc via Globenewswire
(END) Dow Jones Newswires
January 19, 2018 05:15 ET (10:15 GMT)